ONC (BeiGene) Stock Based Compensation : $442 Mil (TTM As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is BeiGene Stock Based Compensation?

BeiGene's Stock Based Compensation for the three months ended in Dec. 2024 was $108 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2024 was $442 Mil.

BeiGene Stock Based Compensation Historical Data

The historical data trend for BeiGene's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Stock Based Compensation Chart

BeiGene Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Stock Based Compensation

Get a 7-Day Free Trial

183.48

240.71

303.16

367.62

441.62

BeiGene Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Stock Based Compensation	Get a 7-Day Free Trial															92.92	88.67	130.64	114.70	107.62

BeiGene Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $442 Mil.

BeiGene Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of BeiGene's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.

BeiGene Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (NAS:ONC) » Definitions » Stock Based Compensation

Comparable Companies

Traded in Other Exchanges

06160:Hong Kong 49B:Germany 688235:China B1ME34:Brazil

Address

c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108

Website

https://www.beigene.com

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.

Executives

Baker Bros. Advisors Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Xiaodong Wang	director	C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Hillhouse Capital Advisors, Ltd.	10 percent owner	OFFICE #122, WINDWARD 3 BUILDING, REGATTA OFFICE PARK, WEST BAY ROAD, GRAND CAYMAN E9 KY1-9006
John Oyler	director, 10 percent owner, officer: Chief Executive Office	C/O GENTA INC, 3550 GENERAL ATOMICS CT BLDG 9, SAN DIEGO CA 92121
Chan Henry Lee	officer: SVP, General Counsel	55 CAMBRIDGE PARKWAY, SUITE 700W, CAMBRIDGE MA 02142
Lai Wang	officer: Global Head of R&D	C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVE, CAMANA BAY, PO BOX 1348, GRAND CAYMAN E9 KY1-1108
Xiaobin Wu	officer: President and GM China	C/O MOURANT OZANNES CRP SVCS CAYMAN LTD, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Julia Aijun Wang	officer: Chief Financial Officer	C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVE, CAMANA BAY, PO BOX 1348, GRAND CAYMAN E9 KY1-1108
Sanders Corazon (corsee) D.	director	C/O MOLECULAR TEMPLATES, INC., 9301 AMBERGLEN BLVD, SUITE 100, AUSTIN VI 78729
Alessandro Riva	director	C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Margaret Dugan	director	C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVE, CAMANA BAY, PO BOX 1348, GRAND CAYMAN E9 KY1-1108
Jane Huang	officer: CMO, Hematology	C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Amgen Inc	10 percent owner	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Howard Liang	officer: CFO & CSO	C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Timothy Yung-cheng Chen	director	LSI LOGIC CORP, 1621 BARBER LANE, MILPITAS CA 95035